Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) shares hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $4.49 and last traded at $4.30, with a volume of 231,104 shares changing hands. The stock had previously closed at $4.12.

A number of research analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, May 24th. Canaccord Genuity set a $10.00 price target on shares of Aurinia Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 5th. Leerink Swann reissued an “outperform” rating and set a $7.00 price target on shares of Aurinia Pharmaceuticals in a research report on Wednesday, July 6th. Finally, HC Wainwright started coverage on shares of Aurinia Pharmaceuticals in a research report on Thursday, June 30th. They set a “buy” rating and a $7.00 price target on the stock. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Aurinia Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $7.15.

The firm’s 50-day moving average price is $3.21 and its 200-day moving average price is $2.77. The stock’s market cap is $132.05 million.

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.